Prognostic value of low skeletal muscle mass in patient treated by exclusive curative radiochemotherapy for a NSCLC

Abstract Low skeletal muscle mass is a well-known prognostic factor for patients treated for a non-small-cell lung cancer by surgery or chemotherapy. However, its impact in patients treated by exclusive radiochemotherapy has never been explored. Our study tries to evaluate the prognostic value of lo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	R. Mallet, P. Decazes, R. Modzelewski, J. Lequesne, P. Vera, B. Dubray, S. Thureau
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/838097ce56c543438398c3f5fa881753
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:838097ce56c543438398c3f5fa881753
record_format	dspace
spelling	oai:doaj.org-article:838097ce56c543438398c3f5fa8817532021-12-02T15:52:47ZPrognostic value of low skeletal muscle mass in patient treated by exclusive curative radiochemotherapy for a NSCLC10.1038/s41598-021-90187-62045-2322https://doaj.org/article/838097ce56c543438398c3f5fa8817532021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-90187-6https://doaj.org/toc/2045-2322Abstract Low skeletal muscle mass is a well-known prognostic factor for patients treated for a non-small-cell lung cancer by surgery or chemotherapy. However, its impact in patients treated by exclusive radiochemotherapy has never been explored. Our study tries to evaluate the prognostic value of low skeletal muscle mass and other antropometric parameters on this population. Clinical, nutritional and anthropometric date were collected for 93 patients treated by radiochemotherapy for a NSCLC. Anthropometric parameters were measured on the PET/CT by two methods. The first method was a manual segmentation at level L3, used to define Muscle Body Area (MBAL3), Visceral Fat Area (VFAL3) and Subcutaneous Fat Area (SCFAL3). The second method was an software (Anthropometer3D), allowing an automatic multislice measurement of Lean Body Mass (LBMAnthro3D), Fat Body Mass (FBMAnthro3D), Muscle Body Mass (MBMAnthro3D), Visceral Fat Mass (VFMAnthro3D), and Sub-Cutaneous Fat Mass (SCFMAnthro3D) on the PET/CT. All anthropometrics parameters were normalised by the patient's height. The primary end point was overall survival time. Univariate and then stepwise multivariate cox analysis were performed for significant parameters. Finally, Spearman's correlation between MBAL3 and MBMAnthro3D was assessed. Forty-one (44%) patients had low skeletal muscle mass. The median overall survival was 18 months for low skeletal muscle mass patients versus 36 months for non-low skeletal muscle mass patients (p = 0.019). Low skeletal muscle mass (HR = 1.806, IC95% [1.09–2.98]), serums albumin level < 35 g/l (HR = 2.203 [1.19–4.09]), Buzby Index < 97.5 (HR = 2.31 [1.23–4.33]), WHO score = 0 (HR = 0.59 [0.31–0.86] and MBMAnthro3D < 8.56 kg/m2 (HR = 2.36 [1.41–3.90]) were the only significant features in univariates analysis. In the stepwise multivariate Cox analysis, only MBMAnthro3D < 8.56 kg/m2 (HR = 2.16, p = 0.003) and WHO score = 0 (HR = 0.59, p = 0.04) were significant. Finally, muscle quantified by MBAL3 and MBMAnthro3D were found to be highly correlated (Spearman = 0.9). Low skeletal muscle mass, assessed on the pre-treatment PET/CT is a powerful prognostic factor in patient treated by radiochemotherapy for a NSCLC. The automatic software Anthropometer3D can easily identify patients a risk that could benefit an adapted therapy.R. MalletP. DecazesR. ModzelewskiJ. LequesneP. VeraB. DubrayS. ThureauNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q R. Mallet P. Decazes R. Modzelewski J. Lequesne P. Vera B. Dubray S. Thureau Prognostic value of low skeletal muscle mass in patient treated by exclusive curative radiochemotherapy for a NSCLC
description	Abstract Low skeletal muscle mass is a well-known prognostic factor for patients treated for a non-small-cell lung cancer by surgery or chemotherapy. However, its impact in patients treated by exclusive radiochemotherapy has never been explored. Our study tries to evaluate the prognostic value of low skeletal muscle mass and other antropometric parameters on this population. Clinical, nutritional and anthropometric date were collected for 93 patients treated by radiochemotherapy for a NSCLC. Anthropometric parameters were measured on the PET/CT by two methods. The first method was a manual segmentation at level L3, used to define Muscle Body Area (MBAL3), Visceral Fat Area (VFAL3) and Subcutaneous Fat Area (SCFAL3). The second method was an software (Anthropometer3D), allowing an automatic multislice measurement of Lean Body Mass (LBMAnthro3D), Fat Body Mass (FBMAnthro3D), Muscle Body Mass (MBMAnthro3D), Visceral Fat Mass (VFMAnthro3D), and Sub-Cutaneous Fat Mass (SCFMAnthro3D) on the PET/CT. All anthropometrics parameters were normalised by the patient's height. The primary end point was overall survival time. Univariate and then stepwise multivariate cox analysis were performed for significant parameters. Finally, Spearman's correlation between MBAL3 and MBMAnthro3D was assessed. Forty-one (44%) patients had low skeletal muscle mass. The median overall survival was 18 months for low skeletal muscle mass patients versus 36 months for non-low skeletal muscle mass patients (p = 0.019). Low skeletal muscle mass (HR = 1.806, IC95% [1.09–2.98]), serums albumin level < 35 g/l (HR = 2.203 [1.19–4.09]), Buzby Index < 97.5 (HR = 2.31 [1.23–4.33]), WHO score = 0 (HR = 0.59 [0.31–0.86] and MBMAnthro3D < 8.56 kg/m2 (HR = 2.36 [1.41–3.90]) were the only significant features in univariates analysis. In the stepwise multivariate Cox analysis, only MBMAnthro3D < 8.56 kg/m2 (HR = 2.16, p = 0.003) and WHO score = 0 (HR = 0.59, p = 0.04) were significant. Finally, muscle quantified by MBAL3 and MBMAnthro3D were found to be highly correlated (Spearman = 0.9). Low skeletal muscle mass, assessed on the pre-treatment PET/CT is a powerful prognostic factor in patient treated by radiochemotherapy for a NSCLC. The automatic software Anthropometer3D can easily identify patients a risk that could benefit an adapted therapy.
format	article
author	R. Mallet P. Decazes R. Modzelewski J. Lequesne P. Vera B. Dubray S. Thureau
author_facet	R. Mallet P. Decazes R. Modzelewski J. Lequesne P. Vera B. Dubray S. Thureau
author_sort	R. Mallet
title	Prognostic value of low skeletal muscle mass in patient treated by exclusive curative radiochemotherapy for a NSCLC
title_short	Prognostic value of low skeletal muscle mass in patient treated by exclusive curative radiochemotherapy for a NSCLC
title_full	Prognostic value of low skeletal muscle mass in patient treated by exclusive curative radiochemotherapy for a NSCLC
title_fullStr	Prognostic value of low skeletal muscle mass in patient treated by exclusive curative radiochemotherapy for a NSCLC
title_full_unstemmed	Prognostic value of low skeletal muscle mass in patient treated by exclusive curative radiochemotherapy for a NSCLC
title_sort	prognostic value of low skeletal muscle mass in patient treated by exclusive curative radiochemotherapy for a nsclc
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/838097ce56c543438398c3f5fa881753
work_keys_str_mv	AT rmallet prognosticvalueoflowskeletalmusclemassinpatienttreatedbyexclusivecurativeradiochemotherapyforansclc AT pdecazes prognosticvalueoflowskeletalmusclemassinpatienttreatedbyexclusivecurativeradiochemotherapyforansclc AT rmodzelewski prognosticvalueoflowskeletalmusclemassinpatienttreatedbyexclusivecurativeradiochemotherapyforansclc AT jlequesne prognosticvalueoflowskeletalmusclemassinpatienttreatedbyexclusivecurativeradiochemotherapyforansclc AT pvera prognosticvalueoflowskeletalmusclemassinpatienttreatedbyexclusivecurativeradiochemotherapyforansclc AT bdubray prognosticvalueoflowskeletalmusclemassinpatienttreatedbyexclusivecurativeradiochemotherapyforansclc AT sthureau prognosticvalueoflowskeletalmusclemassinpatienttreatedbyexclusivecurativeradiochemotherapyforansclc
_version_	1718385582523023360

Prognostic value of low skeletal muscle mass in patient treated by exclusive curative radiochemotherapy for a NSCLC

Ejemplares similares